151 related articles for article (PubMed ID: 37524919)
1. Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classification.
Hochman MJ; Othus M; Hasserjian RP; Ambinder A; Brunner A; Percival MM; Hourigan CS; Swords R; DeZern AE; Estey EH; Karp JE
Leukemia; 2023 Sep; 37(9):1915-1918. PubMed ID: 37524919
[TBL] [Abstract][Full Text] [Related]
2. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study.
Granfeldt Østgård LS; Medeiros BC; Sengeløv H; Nørgaard M; Andersen MK; Dufva IH; Friis LS; Kjeldsen E; Marcher CW; Preiss B; Severinsen M; Nørgaard JM
J Clin Oncol; 2015 Nov; 33(31):3641-9. PubMed ID: 26304885
[TBL] [Abstract][Full Text] [Related]
3. Secondary Acute Myeloid Leukemia (sAML): Similarly Dismal Outcomes of AML After an Antecedent Hematologic Disorder and Therapy Related AML.
Lalayanni C; Gavriilaki E; Athanasiadou A; Iskas M; Papathanasiou M; Marvaki A; Mpesikli S; Papaioannou G; Mallouri D; Batsis I; Papalexandri A; Sakellari I; Anagnostopoulos A
Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):e233-e240. PubMed ID: 34756570
[TBL] [Abstract][Full Text] [Related]
4. Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.
Rausch C; Rothenberg-Thurley M; Dufour A; Schneider S; Gittinger H; Sauerland C; Görlich D; Krug U; Berdel WE; Woermann BJ; Hiddemann W; Braess J; von Bergwelt-Baildon M; Spiekermann K; Herold T; Metzeler KH
Leukemia; 2023 Jun; 37(6):1234-1244. PubMed ID: 37041198
[TBL] [Abstract][Full Text] [Related]
5. Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia.
McCarter JGW; Nemirovsky D; Famulare CA; Farnoud N; Mohanty AS; Stone-Molloy ZS; Chervin J; Ball BJ; Epstein-Peterson ZD; Arcila ME; Stonestrom AJ; Dunbar A; Cai SF; Glass JL; Geyer MB; Rampal RK; Berman E; Abdel-Wahab OI; Stein EM; Tallman MS; Levine RL; Goldberg AD; Papaemmanuil E; Zhang Y; Roshal M; Derkach A; Xiao W
Blood Adv; 2023 Sep; 7(17):5000-5013. PubMed ID: 37142255
[TBL] [Abstract][Full Text] [Related]
6. Defining Acute Myeloid Leukemia Ontogeny in Older Patients.
Melody M; Kuykendall A; Sallman D; Al Ali N; Zhang L; Talati C; Padron E; Sweet K; Extermann M; List A; Lancet J; Komrokji R
Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):312-315. PubMed ID: 32139296
[TBL] [Abstract][Full Text] [Related]
7. Elderly Patients (Age 70 Years or Older) With Secondary Acute Myeloid Leukemia or Acute Myeloid Leukemia Developed Concurrently to Another Malignant Disease.
Collinge E; Loron S; Larcher MV; Elhamri M; Heiblig M; Deloire A; Ducastelle S; Labussière H; Barraco F; Wattel E; Salles G; Paubelle E; Thomas X
Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):e211-e218. PubMed ID: 29572159
[TBL] [Abstract][Full Text] [Related]
8. ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantation.
Jentzsch M; Grimm J; Bill M; Brauer D; Backhaus D; Goldmann K; Schulz J; Niederwieser D; Platzbecker U; Schwind S
Bone Marrow Transplant; 2021 Apr; 56(4):936-945. PubMed ID: 33208914
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of genetic aberrations in secondary acute myeloid leukemia.
Milosevic JD; Puda A; Malcovati L; Berg T; Hofbauer M; Stukalov A; Klampfl T; Harutyunyan AS; Gisslinger H; Gisslinger B; Burjanivova T; Rumi E; Pietra D; Elena C; Vannucchi AM; Doubek M; Dvorakova D; Robesova B; Wieser R; Koller E; Suvajdzic N; Tomin D; Tosic N; Colinge J; Racil Z; Steurer M; Pavlovic S; Cazzola M; Kralovics R
Am J Hematol; 2012 Nov; 87(11):1010-6. PubMed ID: 22887079
[TBL] [Abstract][Full Text] [Related]
10. Characteristics and Outcomes of Secondary Acute Myeloid Leukemia and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Multicenter Study From the Thai Acute Leukemia Study Group.
Chanswangphuwana C; Polprasert C; Owattanapanich W; Kungwankiattichai S; Tantiworawit A; Rattanathammethee T; Limvorapitak W; Saengboon S; Niparuck P; Puavilai T; Julamanee J; Saelue P; Wanitpongpun C; Nakhakes C; Prayongratana K; Sriswasdi C
Clin Lymphoma Myeloma Leuk; 2022 Dec; 22(12):e1075-e1083. PubMed ID: 36117042
[TBL] [Abstract][Full Text] [Related]
11. Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia.
Lo MY; Tsai XC; Lin CC; Tien FM; Kuo YY; Lee WH; Peng YL; Liu MC; Tseng MH; Hsu CA; Chen JC; Lin LI; Sun HI; Chuang YK; Ko BS; Tang JL; Yao M; Chou WC; Hou HA; Tien HF
Am J Hematol; 2023 May; 98(5):760-769. PubMed ID: 36861732
[TBL] [Abstract][Full Text] [Related]
12. Survival difference between secondary and de novo acute myeloid leukemia by age, antecedent cancer types, and chemotherapy receipt.
Sedeta E; Jemal A; Nisotel L; Sung H
Cancer; 2024 Jun; 130(11):1952-1963. PubMed ID: 38244208
[TBL] [Abstract][Full Text] [Related]
13. Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes.
Boddu PC; Kadia TM; Garcia-Manero G; Cortes J; Alfayez M; Borthakur G; Konopleva M; Jabbour EJ; Daver NG; DiNardo CD; Naqvi K; Yilmaz M; Short NJ; Pierce S; Kantarjian HM; Ravandi F
Cancer; 2019 Apr; 125(7):1091-1100. PubMed ID: 30521114
[TBL] [Abstract][Full Text] [Related]
14. Assessment of 2022 European LeukemiaNet risk classification system in real-world cohort from China.
Chen E; Jiao C; Yu J; Gong Y; Jin D; Ma X; Cui J; Wu Z; Zhou J; Wang H; Su B; Ge J
Cancer Med; 2023 Dec; 12(24):21615-21626. PubMed ID: 38098254
[TBL] [Abstract][Full Text] [Related]
15. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry.
Hulegårdh E; Nilsson C; Lazarevic V; Garelius H; Antunovic P; Rangert Derolf Å; Möllgård L; Uggla B; Wennström L; Wahlin A; Höglund M; Juliusson G; Stockelberg D; Lehmann S
Am J Hematol; 2015 Mar; 90(3):208-14. PubMed ID: 25421221
[TBL] [Abstract][Full Text] [Related]
16. Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study.
Harada Y; Nagata Y; Kihara R; Ishikawa Y; Asou N; Ohtake S; Miyawaki S; Sakura T; Ozawa Y; Usui N; Kanamori H; Ito Y; Imai K; Suehiro Y; Kobayashi S; Kitamura K; Sakaida E; Onizuka M; Takeshita A; Ishida F; Suzushima H; Ishizawa K; Naoe T; Matsumura I; Miyazaki Y; Ogawa S; Kiyoi H;
Leuk Res; 2018 Mar; 66():20-27. PubMed ID: 29360622
[TBL] [Abstract][Full Text] [Related]
17. Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia.
Lachowiez CA; Long N; Saultz J; Gandhi A; Newell LF; Hayes-Lattin B; Maziarz RT; Leonard J; Bottomly D; McWeeney S; Dunlap J; Press R; Meyers G; Swords R; Cook RJ; Tyner JW; Druker BJ; Traer E
Blood Adv; 2023 May; 7(9):1899-1909. PubMed ID: 36441905
[TBL] [Abstract][Full Text] [Related]
18. Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years.
Eisfeld AK; Kohlschmidt J; Mims A; Nicolet D; Walker CJ; Blachly JS; Carroll AJ; Papaioannou D; Kolitz JE; Powell BE; Stone RM; de la Chapelle A; Byrd JC; Mrózek K; Bloomfield CD
Leukemia; 2020 Dec; 34(12):3215-3227. PubMed ID: 32461631
[TBL] [Abstract][Full Text] [Related]
19. Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.
Herold T; Rothenberg-Thurley M; Grunwald VV; Janke H; Goerlich D; Sauerland MC; Konstandin NP; Dufour A; Schneider S; Neusser M; Ksienzyk B; Greif PA; Subklewe M; Faldum A; Bohlander SK; Braess J; Wörmann B; Krug U; Berdel WE; Hiddemann W; Spiekermann K; Metzeler KH
Leukemia; 2020 Dec; 34(12):3161-3172. PubMed ID: 32231256
[TBL] [Abstract][Full Text] [Related]
20. Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results.
Gardin C; Pautas C; Fournier E; Itzykson R; Lemasle E; Bourhis JH; Adès L; Marolleau JP; Malfuson JV; Gastaud L; Raffoux E; Lambert J; Braun T; Thomas X; Chantepie S; Cluzeau T; de Botton S; Berthon C; Boissel N; Duployez N; Terré C; Peffault de Latour R; Michallet M; Celli-Lebras K; Preudhomme C; Dombret H
Blood Adv; 2020 May; 4(9):1942-1949. PubMed ID: 32380535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
